Replimune Group Target of Unusually Large Options Trading (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL) saw some unusual options trading activity on Tuesday. Traders purchased 11,386 call options on the company. This represents an increase of 653% compared to the typical daily volume of 1,513 call options.

Analysts Set New Price Targets

A number of research firms have weighed in on REPL. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Replimune Group in a research note on Thursday, July 3rd. Piper Sandler raised their target price on shares of Replimune Group from $14.00 to $22.00 and gave the company an “overweight” rating in a research note on Monday, June 2nd. Finally, Cantor Fitzgerald assumed coverage on shares of Replimune Group in a research report on Friday, June 20th. They set an “overweight” rating on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $20.83.

Replimune Group Stock Up 9.9%

REPL stock opened at $12.40 on Wednesday. Replimune Group has a 1-year low of $6.44 and a 1-year high of $17.00. The business’s 50 day simple moving average is $9.24 and its 200 day simple moving average is $10.48. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $955.92 million, a PE ratio of -4.04 and a beta of 0.61.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the company earned ($0.25) EPS. As a group, research analysts anticipate that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,952 shares of the firm’s stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the transaction, the insider owned 146,933 shares of the company’s stock, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Sushil Patel sold 25,105 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $202,346.30. Following the completion of the sale, the chief executive officer owned 343,576 shares in the company, valued at $2,769,222.56. The trade was a 6.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 74,907 shares of company stock valued at $603,655 over the last ninety days. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of REPL. Sterling Capital Management LLC boosted its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after acquiring an additional 1,655 shares during the period. US Bancorp DE lifted its holdings in Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after purchasing an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd grew its holdings in Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Replimune Group by 897.2% during the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company’s stock worth $902,000 after buying an additional 7,913 shares during the period. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.